ASCO 24: Data shows survival benefit with J&J's subcutaneous

J&J's Rybrevant is expected to generate $4bn in sales by 2030, as per GlobalData estimates.

Related Keywords

United States , American , Astrazeneca Tagrisso , European Medicines Agency , American Society Of Clinical Oncology , American Society , Clinical Oncology , Annual Meeting , Johnson Innovative Medicine , Biologics License Application , Clinical Trials Arena ,